Commercialization of mCOMBRIAX in Europe through pricing, reimbursement and tenders, with contribution expected to begin in 2027 and expand in 2028.
Potential U.S. approval and launch of Moderna's seasonal flu vaccine mRNA-1010 following the August 5, 2026 PDUFA date.
Dedicated Intismeran manufacturing facility in Massachusetts preparing for potential commercial launch next year if the Phase III adjuvant melanoma readout supports accelerated review.
Additional U.K. government vaccine delivery for the fall booster campaign in the third and fourth quarters of 2026.
Brazil strategic-partnership expansion through a local manufacturing agreement supporting multiyear government supply of COVID vaccines.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Moderna, Inc. and 4,900+ companies.